SCHAUMBURG, Ill., June 02, 2025--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Leuprolide Acetate ...
Enzalutamide Plus Leuprolide Extends Treatment Suspension in Biochemically Recurrent Prostate Cancer
An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...
MUMBAI, India and WARREN, N.J., Nov. 29, 2022 /PRNewswire/ -- Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) and its wholly owned subsidiary Cipla USA Inc. (hereafter referred to as 'Cipla'), today ...
Read the Medication Guide provided by your pharmacist before you start using leuprolide and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is ...
Cipla Limited and its wholly owned subsidiary Cipla USA Inc., has announced the launch of leuprolide acetate injection depot 22.5mg. The product was approved by the United States Food and Drug ...
Leuprolide Acetate injection is indicated in the palliative treatment of advanced prostatic cancer. Leuprolide Acetate injections will be manufactured at the Company's oncology injectable ...
Credit: Getty Images. Camcevi is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, a gonadotropin-releasing hormone agonist. Camcevi ® (leuprolide mesylate) 42mg injection ...
This open-label study evaluated the efficacy and safety of a new leuprolide acetate 45 mg 6-month depot formulation in 151 men with prostate cancer who received 2 intramuscular injections administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results